Bastion Asset Management Inc. Makes New $4.64 Million Investment in Omnicell, Inc. $OMCL

Bastion Asset Management Inc. bought a new position in Omnicell, Inc. (NASDAQ:OMCL) during the first quarter, Holdings Channel.com reports. The firm bought 131,647 shares of the company’s stock, valued at approximately $4,638,000.

Several other institutional investors also recently modified their holdings of OMCL. Dimensional Fund Advisors LP lifted its holdings in Omnicell by 9.1% during the third quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after acquiring an additional 197,462 shares during the period. Wellington Management Group LLP grew its stake in Omnicell by 156.4% in the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after purchasing an additional 1,265,818 shares during the period. Lazard Asset Management LLC increased its position in shares of Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after purchasing an additional 62,733 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Omnicell by 2.0% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after purchasing an additional 27,497 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Omnicell by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock worth $51,088,000 after purchasing an additional 11,424 shares during the period. 97.70% of the stock is owned by institutional investors.

Omnicell Stock Up 0.4%

OMCL stock opened at $47.00 on Friday. The stock has a fifty day moving average of $42.53 and a 200-day moving average of $41.51. Omnicell, Inc. has a fifty-two week low of $26.84 and a fifty-two week high of $55.00. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of 106.82, a PEG ratio of 1.21 and a beta of 0.96. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.26 EPS. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, equities research analysts predict that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Insider Activity

In other news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Craig Hallum restated a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Wednesday, April 29th. KeyCorp lifted their price objective on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 28th. Wells Fargo & Company boosted their target price on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, April 23rd. Finally, Zacks Research downgraded shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $59.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.